Drug Trial Radar · NCT07220577
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
34
Actual
Start
Nov 10, 2025
Primary completion
May 17, 2027
Study completion Sep 6, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
GIA632Drug
Active treatment arm
PlaceboOther
Placebo treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- IGA response at Week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baselineTime frame: Baseline, Week 16
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
Ctr for Dermatology Clinical Res
Fremont, California
Aesthetics Skin Care Dermatologic Surgery
Rockville, Maryland
Care Access Hoboken
Hoboken, New Jersey
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Ostrava, Poruba, Czechia
Novartis Investigative Site
Antony, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Martigues, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Kuala Lumpur, Malaysia
Novartis Investigative Site
Ipoh, Perak, Malaysia
Novartis Investigative Site
George Town, Pulau Pinang, Malaysia
Novartis Investigative Site
Kota Kinabalu, Sabah, Malaysia
Novartis Investigative Site
Gdansk, Poland
Novartis Investigative Site
Torun, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.